Track 11 explores open source solutions in the life sciences software development vs. licensing, collaborative research models, data security and regulations, patents and IP on key technologies and research tools, data integration that provide exchange support for a wide variety of basic, clinical and translational research efforts.
Download Brochure | Pre-Conference Workshops
TUESDAY, APRIL 9
7:00 am Workshop Registration and Morning Coffee
8:00 Pre-Conference Workshops*
*Separate Registration Required
2:00 - 7:00 pm Main Conference Registration
- 4:00 Event Chairperson’s Opening Remarks
Cindy Crowninshield, RD, LDN, Conference Director, Cambridge Healthtech Institute
4:05 Keynote Introduction
Kevin Brode, Senior Director, Health & Life Sciences, Americas Hitachi Data Systems
» 4:15 PLENARY KEYNOTE
Do Network Pharmacologists Need Robot Chemists?
Andrew L. Hopkins, DPhil, FRSC, FSB, Division of Biological Chemistry and Drug Design, College of Life Sciences, University of Dundee
10 Minute Welcome to the Reception!
Mike Nolte, Regional Sales Manager – East, Okta
5:00 Welcome Reception in the Exhibit Hall with Poster Viewing
Drop off a business card at the CHI Sales booth for a chance to win 1 of 2 iPads® or 1 of 2 Kindle Fires®!*
*Apple® is not a sponsor or participant in this program
WEDNESDAY, APRIL 10
7:00 am Registration and Morning Coffee
8:00 Chairperson’s Opening Remarks
Phillips Kuhl, Co-Founder and President, Cambridge Healthtech Institute
8:05 Keynote Introduction
Sanjay Joshi, CTO, Life Sciences, EMC Isilon
» 8:15 PLENARY KEYNOTE
Atul Butte, M.D., Ph.D., Division Chief and Associate Professor, Stanford University School of Medicine; Director, Center for Pediatric Bioinformatics, Lucile Packard Children's Hospital; Co-founder, Personalis and Numedii
8:55 Benjamin Franklin Award & Laureate Presentation
9:15 Best Practices Award Program
9:45 Coffee Break in the Exhibit Hall with Poster Viewing
10:50 Chairperson’s Remarks
Peter Hussey, Founding Partner, LabKey Software
11:00 The Pistoia Alliance: Pre-competitive Collaboration, Translational Research, and the Appification of Science
Ramesh Durvasula, Ph.D., Director, Research Informatics, Bristol-Myers Squibb; Board Member, Pistoia Alliance
For several years, the Pistoia Alliance has pushed the envelope in pre-competitive collaborations in research informatics. In this talk, we will share our strategy of two key priorities: enabling Translational Research collaborations, and the highly potential energy of "apps" in our industry. Both of these subjects require strong cross-industry collaboration, and we will discuss how Pistoia is lowering the barriers to innovation in the life sciences.
11:30 Creating an Intelligent and Automated Analytical Laboratory
Dana Vanderwall, Associate Director, Research Informatics and Automation, Bristol Myers Squibb
Imagine an intelligent analytical laboratory where one-click reports can be generated from any analytical instrument platform. An automated laboratory where data, methods, hardware components are seamlessly shared between disparate platforms. This presentation will introduce the current effort of the Allotrope Foundation, a consortium of pharmaceutical companies, in developing an open-source Framework for managing analytical data generated by different analytical platforms.
12:00 pm GGA Software Services’ Indigo ELN: The Open-Source Version of Pfizer’s Chemistry ELN
Steven Trudel, Business Partner, Chemistry and Pharmacology, Pfizer, Inc.
Yuriy Gankin, Ph.D., Chief Scientific Officer, GGA Software Services LLC
GGA Software Services has partnered with Pfizer to develop and offer Indigo ELN, an open-source version of Pfizer’s Chemistry Electronic Lab Notebook. Indigo ELN can be deployed internally at pharmaceutical companies or externally at partners and vendors. It offers pharmaceutical companies a cost-effective way for their partner ecosystem to collect and share data in a standardized format. This talk will describe the history and benefits of Indigo ELN; its uses for preparing, planning, and analyzing experiments; and its capability to integrate with commercial products and other open-source applications.
12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
1:40 Chairperson’s Remarks
Scott Wilkins, Informatics Director, R&D Information, AstraZeneca
1:45 The Lilly Open Innovation Drug Discovery Program (OIDD)
Daniel Robertson, Ph.D., Senior Director, LRL IT Research, Eli Lilly & Co.
Through OIDD, Lilly has established a network of top global research talent at academic and biotech institutions to provide them access to proprietary, in vitro phenotypic and target-based assays (PD2 and TargetD2). This partnership is supported by the program’s website portal and application, which lowers the barrier for collaborations between investigators working inside and outside the Lilly walls.
2:15 Can Data Fly? Multiple Stakeholders Advance Data Liquidity for Cancer Research and Care
Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare
Kris Joshi, Vice President, Global Health Sciences, Oracle
Following the 2012 Institute of Medicine workshop on Cancer Informatics, concerned stakeholders from every segment of the biomedical ecosystem got together to address the huge technical and cultural obstacles. The Data Liquidity Coalition is now up and running, designing practical projects and advocating for policy change to drive standards-based capabilities for seamless data exchange.
2:45 Developing a Global Innovation Capability to Accelerate R&D Productivity
Scott Wilkins, Informatics Director, R&D Information, AstraZeneca
Kris Nayak ; Nick Brown ; Valerie Marone ; and Todd Nelson 
 AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TF United Kingdom
 AstraZeneca, 35 Gatehouse Drive Waltham, MA 02451
Producing new medicines that are safe and efficacious creates numerous challenges along the way during the years they take to research and develop. At AstraZeneca, we have approximately 10,000 R&D colleagues with scientific and medical expertise around the world. This is a great asset but our colleagues are spread across multiple locations, tend to be focused on specific tasks, and interact with a limited number of people. Consequently, there’s a significant opportunity to better enable our experts to solve important scientific challenges regardless of location, or therapeutic area.To enable this, we’ve launched global cultural and technical initiatives to increase collaborative behaviors and deliver a new innovation platform to connect scientists around the world to solve our most challenging scientific problems. In 2012, we launched our first innovation platform through which R&D colleagues can post challenges globally and connect colleagues regardless of where their laboratory is located, or what therapeutic area they’re in. As a result, we’ve successfully connected people to find solutions to challenges and have a more integrated approach to solving important scientific challenges which include the discovery new classes of therapeutics, improving safety of clinical trials, and optimizing synthesis of therapeutics in development and those commercialized. We recently launched a global Challenge campaign across R&D supported by our innovation platform that connected 5,000 scientists and developed multiple solutions one of which received $1 Million of project funding. Today, we’ve connected over 7,000 scientists to solve multiple R&D Challenges thus increasing our productivity as an organization to bring the best medicines to patients as soon as possible. Our next steps are to build on the success within our R&D organisation to bridge across other corporate functions, and create an integrated innovation ecosystem to connect external partners as well.
3:15 Refreshment Break in the Exhibit Hall with Poster Viewing
3:45 The Multiple Myeloma Research Portal: Integration of Analytic Tools and Data Mining of Clinical and Molecular Data to Fuel Research and Drug Discovery
Carolyn Hoban, Sc.D., MMRF, Director, Translational Research, Multiple Myeloma Research Foundation
We will present the design of the research and community portal that opens new models for collaborative research, data sharing and hypothesis generation. The longitudinal study, CoMMpass, tracking genome wide changes associated with the natural history of myeloma from diagnosis through treatment serves as the data foundation for creating a world class knowledge base in the ‘omics of myeloma.
4:15 Open Source, Open Medicine, Open Mind
Andreas Kogelnik, MD, Ph.D., Founder, Open Medicine Institute
The Open Medicine Institute was founded on the principle of open source code, to promote healthcare innovation via collaboration and focus on tackling diseases such as Autism, Chronic Fatigue, Multiple Sclerosis. Details of the OpenMedNet system and examples of collaborative interaction leading to improved medical outcomes will be discussed.
4:45 Productivity and Quality Benefits from a Platform Enabled Authoring Environment
Dennis Curran, Director, Product Management, Accelrys
Research is no longer an isolated researcher running a series of related experiments following a single key hypothesis. Many of today’s researchers have a wide array of real time dependencies on both internal and external associates in order to complete an experimental program. The documentation and authoring tools must advance to enable the planning, data capture, and analysis to be performed without constant switching between applications, emails, file servers, and paper printouts. The Accelrys Electronic Lab Notebook offers an advanced platform for aggregating data from multiple sources when creating the experimental records necessary for IP and Regulatory obligations. The Accelrys Enterprise Platform helps eliminate manual data transformations and cut and paste operations by integrating into your laboratory tools and providing quality and timely data operations.
5:15 Best of Show Awards Reception in the Exhibit Hall
6:15 Exhibit Hall Closes
Thursday, April 11
7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee
8:45 Chairperson’s Opening Remarks
Xue-wen Chen, Ph.D., Department Chair & Professor, Computer Science, Wayne State University
8:50 tranSMART: A Year of Innovation and Growth of an Open Source Community
Dan Housman, Community Manager and Member, Project Management/Oversight Team, tranSMART Project; Chief Technology Officer, Recombinant Data Corp.
Eight of the top twelve biopharmaceutical companies have adopted tranSMART, the knowledge management platform originally developed to share drug research and development data within Johnson & Johnson. Since its release into open source in April 2012, a community of industry and academic leaders has formed, all of whom seek to innovate and collaborate toward a shared vision.
9:20 Reproducible Research: Using Open Source Tools and Public Data to Build Machine Learning Models in Support of Antimalarial Drug Discovery
Paul Kowalczyk, Ph.D., Senior Computational Chemist, Integrated Parasitology, SCYNEXIS
We present our efforts at developing machine learning models in support of antimalarial drug discovery. The data is in the public domain, and the tools are open-source. The resulting models are meant to be freely shared among collaborators. The models are made available with all elements required to reproduce, expand and update. The models represent an instantiation of reproducible research.
9:50 Open, Collaborative, and Transformative: Exploring and Connecting Bioactive Chemistry Across Biomedical Documents and Databases with Public Tools
Christopher Southan, Ph.D., Principal Consultant, TW2Informatics
Although there are ~ 50 million chemical structure in public databases, many millions of bioactive compounds are still entoombed in documents. In addition linking chemistry between patents, papers, abstracts and databases has been patchy. However, new tools such as chemicalize.org, OPSIN, OSCA, Venny, CheS-Mapper and InChIKey indexing by Google, have transformed the extraction, analysis and connectivity of structures from text. Extractions can also be triaged against PubChem that now contains 14.5 million patent-extracted compounds from SureChemOpen, SCRIPDB, Thomson and IBM as well as 1 million from journals via ChEMBL and PubMed. These advances present new collaborative options such as sharing extracted neglected disease patents with SAR annotations on Figshare.
10:20 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced
10:45 Plenary Keynote Panel Chairperson’s Remarks
Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World
10:50 Plenary Keynote Panel Introduction
Yury Rozenman, Head of BT for Life Sciences, BT Global Services
Niven R. Narain, President & CTO, Berg Pharma
» PLENARY KEYNOTE PANEL
11:05 The Life Sciences CIO Panel
Remy Evard, CIO, Novartis Institutes for BioMedical Research
Martin Leach, Ph.D., Vice President, R&D IT, Biogen Idec
Andrea T. Norris, Director, Center for Information Technology (CIT) and Chief Information Officer, NIH
Gunaretnam (Guna) Rajagopal, Ph.D., VP & CIO - R&D IT, Research, Bioinformatics & External Innovation, Janssen Pharmaceuticals
Cris Ross, Chief Information Officer, Mayo Clinic
Matthew Trunnell, CIO, Broad Institute of MIT and Harvard
12:15 Luncheon in the Exhibit Hall with Poster Viewing
1:55 Chairperson’s Remarks
Mollie Shields-Uehling, MA, President and CEO, SAFE-BioPharma Association
2:00 Collaboration within the Pharma Industry to Improve the Quality of Clinical Studies and Bring New Medicines to Patients Faster
Laurie Milligan, Director, IT Strategy, R&D IT, Medicines Development Capabilities, GlaxoSmithKline
The Pharma industry continues to simplify aspects of clinical development by focusing on people, process, standards, and technology. This is a fundamental transformation in the ways we work and the ways we use technology. To achieve this, we should consider our internal organizations as well as collaboration across the industry.
2:30 The Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Platform as a Unique Industry, Academic, and Foundation Collaboration to Generate a Novel Research Resource
Alexander Sherman, Director, Systems, Neurological Clinical Research Institute, Massachusetts General Hospital
A Pooled Resource Open-access ALS Clinical Trials (PRO-ACT) platform allows merging of data from existing public and private sources of completed Phase II and III trials. Data mining of PRO-ACT is expected to lead to the identification of disease biomarkers, provide insight into the natural history of disease, as well as insights into the design and interpretation of clinical trials.
3:00 Advancing Translational Research through Web-Portal Access to Clinical Trials Data, Analyses and Bio-Repository Information
Adam Asare, Ph.D., Senior Director, Data Analysis & Data Management, Biomarker & Discovery Research, Immune Tolerance Network (ITN)
The Immune Tolerance Network has developed ITN TrialShare, a web portal application providing research collaborators access to clinical, research assay and specimen data along with tools for data visualization and collaborations. Hear lessons learned from committing to an open source software framework, ongoing challenges with clinical trials and research assay data management, latest projects, and issues with HIPAA compliance.
3:30 The Image Collaborative Portal: A Distributed Solution Driving Substantial Cost Savings in Managing Imaging Clinical Trials
Jay Bergeron, Senior Manager, Translational and Bioinformatics, Pfizer, Inc.
Collecting medical images from multi-site clinical trials requires substantial coordination across acquisition sites, safety monitors, and sponsors. The Image Collaborative Portal (ICP) is used to substantially contain costs by alleviating the need for a CRO image custodian. Learn how this distributed approach to image study management via cloud services, presents a new scalable, extensible and cost effective model for study conduct.
4:00 Conference Adjourns
Download Brochure | Pre-Conference Workshops